Skip to main content

MeiraGTx to Participate in Upcoming Virtual Investor Conferences

Written by Customer Service on . Posted in Public Companies.

LONDON and NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following virtual investor conferences:

  • Barclays Gene Editing & Gene Therapy Summit

Corporate presentation: Monday, November 15, 2021, at 2:00 p.m. ET

  • 33rd Annual Piper Sandler Healthcare Conference

Fireside chat: available from Monday, November 22, 2021, at 10:00 a.m. ET to Thursday, December 2, 2021 for registered attendees via the Piper Sandler conference site.

  • Evercore ISI 4th Annual HealthCONx

Corporate presentation: Tuesday, November 30, 2021, at 10:05 a.m. ET

A live webcast of the corporate presentations and the recording of the Piper Sandler fireside chat will be available on the Investors page of the Company’s website at investors.meiragtx.com. Replays will be available for approximately 30 days following the presentation dates.

About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: ocular, including inherited retinal diseases and large degenerative diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit www.meiragtx.com.

Contacts

Investors:
MeiraGTx
Investors@meiragtx.com

(646) 860-7982


Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.